MPCI Stock Overview
A drug holding company, produces and sells pharmaceutical products for human and veterinary use in Egypt and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Memphis Pharmaceuticals & Chemical Industries Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م79.63 |
| 52 Week High | ج.م107.00 |
| 52 Week Low | ج.م31.00 |
| Beta | 0.18 |
| 1 Month Change | 37.34% |
| 3 Month Change | 51.04% |
| 1 Year Change | -21.35% |
| 3 Year Change | 443.55% |
| 5 Year Change | 626.55% |
| Change since IPO | 163.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| MPCI | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -5.2% | -2.3% | 0.2% |
| 1Y | -21.3% | 16.0% | 15.5% |
Return vs Industry: MPCI underperformed the EG Pharmaceuticals industry which returned 15% over the past year.
Return vs Market: MPCI underperformed the EG Market which returned 17.5% over the past year.
Price Volatility
| MPCI volatility | |
|---|---|
| MPCI Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in EG Market | 8.3% |
| 10% least volatile stocks in EG Market | 2.8% |
Stable Share Price: MPCI's share price has been volatile over the past 3 months compared to the EG market.
Volatility Over Time: MPCI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of EG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1940 | n/a | Bassem Abdullah | www.memphis.com.eg |
Memphis Pharmaceuticals & Chemical Industries, a drug holding company, produces and sells pharmaceutical products for human and veterinary use in Egypt and internationally. The company offers human health products in various therapeutic areas, including anti-infective, CNS, dermatological, cardio vascular system, corticosteroid, vitamins and minerals, musculo-skeletal system, analgesic and antipyretic, respiratory system, genitourinary system, alimentary tract and metabolism, antihistaminic, antiparasites, and hormones. It also provides animal health products in powder form, as well as in oral and injectable solution forms.
Memphis Pharmaceuticals & Chemical Industries Fundamentals Summary
| MPCI fundamental statistics | |
|---|---|
| Market cap | ج.م1.81b |
| Earnings (TTM) | ج.م376.65m |
| Revenue (TTM) | ج.م1.23b |
4.8x
P/E Ratio1.5x
P/S RatioIs MPCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPCI income statement (TTM) | |
|---|---|
| Revenue | ج.م1.23b |
| Cost of Revenue | ج.م710.28m |
| Gross Profit | ج.م519.76m |
| Other Expenses | ج.م143.10m |
| Earnings | ج.م376.65m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.56 |
| Gross Margin | 42.26% |
| Net Profit Margin | 30.62% |
| Debt/Equity Ratio | 30.1% |
How did MPCI perform over the long term?
See historical performance and comparisonDividends
5.0%
Current Dividend Yield6%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/20 05:54 |
| End of Day Share Price | 2025/03/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Memphis Pharmaceuticals & Chemical Industries is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.